



LUND UNIVERSITY

Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions

Dickneite, Gerhard; Herwald, Heiko; Korte, Wolfgang; Allanore, Yannick; Denton, Christopher P.; Cerinic, Marco Matucci

Published in:
Thrombosis and Haemostasis

DOI:
[10.1160/TH14-07-0625](https://doi.org/10.1160/TH14-07-0625)

2015

[Link to publication](#)

Citation for published version (APA):

Dickneite, G., Herwald, H., Korte, W., Allanore, Y., Denton, C. P., & Cerinic, M. M. (2015). Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. *Thrombosis and Haemostasis*, 113(4), 686-697. <https://doi.org/10.1160/TH14-07-0625>

Total number of authors:
6

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions

Gerhard Dickneite¹; Heiko Herwald²; Wolfgang Korte³; Yannick Allanore⁴; Christopher P. Denton⁵; Marco Matucci Cerinic⁶

¹Preclinical Research & Development, CSL Behring GmbH, Marburg, Germany;

²Department of Clinical Sciences, Lund University, Lund, Sweden;

³Centre for Laboratory Medicine and Haemostasis and Haemophilia Centre, St Gallen, Switzerland;

⁴Department of Rheumatology A, Paris Descartes University, APHP, Hôpital Cochin, Paris, France;

⁵Centre for Rheumatology, UCL Medical School, Royal Free Campus, London, UK;

⁶Department of Experimental and Clinical Medicine, Careggi Hospital (AOUC), University of Florence, Florence, Italy

Correspondence to: Prof. Dr Gerhard Dickneite, Preclinical R&D, CSL Behring, PO Box 1230, 35002 Marburg, Germany

Tel.: +49 6421 392306

Fax: +49 6421 394663

E-mail: gerhard.dickneite@cslbehring.com

Running title: Therapeutic potential of factor XIII

Word count: 5066 words (excluding abstract, references, footnote, acknowledgements, table and figure legends)

Conflicts of interest

G. Dickneite is an employee of CSL Behring GmbH and owns CSL Behring stock. CSL Behring GmbH (Marburg, Germany) and Hansa Medical AB (Lund, Sweden) have filed a patent application on FXIII. G. Dickneite and H. Herwald are listed as inventors. W. Korte has received research support and speaker fees from CSL Behring and Novo Nordisk, and holds and has filed patents on point-of-care tests for FXIII, as well as preoperative identification of patients at risk for intraoperative bleeding complications. Y. Allanore has received honoraria from CSL Behring, Actelion, Bayer, Sanofi, Roche and Pfizer. C Denton has received research grants from Actelion and consulted for Actelion, Pfizer, GSK, Roche, CSL Behring, Sanofi and Merck.

Summary

Coagulation factor XIII (FXIII), a plasma transglutaminase, is best known as the final enzyme in the coagulation cascade, where it is responsible for cross-linking of fibrin. However, a growing body of evidence has demonstrated that FXIII targets a wide range of additional substrates that have important roles in health and disease. These include antifibrinolytic proteins, with cross-linking of α_2 -antiplasmin to fibrin, and potentially fibrinogen, being the principal mechanism(s) whereby plasmin-mediated clot degradation is minimised. FXIII also acts on endothelial cell VEGFR-2 and $\alpha_v\beta_3$ integrin, which ultimately leads to downregulation of the antiangiogenic protein thrombospondin-1, promoting angiogenesis and neovascularisation. Under infectious disease conditions, FXIII cross-links bacterial surface proteins to fibrinogen, resulting in immobilisation and killing, while during wound healing, FXIII induces cross-linking of the provisional matrix. The latter process has been shown to influence the interaction of leukocytes with the provisional extracellular matrix and promote wound healing. Through these actions, there are good rationales for evaluating the therapeutic potential of FXIII in diseases in which tissue repair is dysregulated or perturbed, including systemic sclerosis (scleroderma), invasive bacterial infections, and tissue repair, for instance healing of venous leg ulcers or myocardial injuries. Adequate levels of FXIII are also required in patients undergoing surgery to prevent or treat perioperative bleeding, and its augmentation in patients with/at risk for perioperative bleeding may also have potential clinical benefit. While there are preclinical and/or clinical data to support the use of FXIII in a range of settings, further clinical evaluation in these underexplored applications is warranted.

(Word count: 250 words; limit 250 words)

Keywords

Coagulation, factor XIII, infection, scleroderma, wound healing

Introduction

Factor XIII (FXIII) is the final enzyme in the coagulation cascade and it plays a key role in maintaining the functional integrity of fibrin clots. This coagulation factor circulates in plasma as a protransglutaminase that consists of two catalytic A subunits and two carrier/protective B subunits (1, 2). The A subunits contain the catalytic component, activation peptide and the substrate-recognition regions of FXIII; they are found bound to B subunits in plasma or alone as intracellular homodimers (2, 3).

FXIII is activated by thrombin (factor IIa) to form a transglutaminase that catalyses covalent bond formation between the γ -carboxyamine group of a glutamine residue and the ϵ -amino group of a lysine residue. During clot formation, stability is achieved through covalent cross-linking of fibrin γ - and α -chains and covalent binding of antifibrinolytic proteins to fibrin (2, 4). The critical function of FXIII in haemostasis is reflected in the broad spectrum of bleeding complications that is observed in patients with congenital FXIII deficiency, a rare autosomal recessive trait (5). Patients often suffer from umbilical stump bleeding, subcutaneous bleeding, muscle haemorrhage, postoperative haemorrhage, and potentially fatal intracranial haemorrhage, the latter occurring in approximately one-third (34%) of patients (5). Among rare bleeding disorders, FXIII deficiency is associated with the highest proportion of severe bleeding episodes, underscoring the importance of this coagulation factor in normal haemostasis (6). Another clinical feature in patients with congenital FXIII deficiency is poor and slow wound healing (7). FXIII deficiency is not identified by standard coagulation testing, and the lack of a readily available and accurate test for the condition hampers diagnosis, particularly in less severe cases (4). FXIII concentrate (human) is recommended as prophylactic treatment for patients with congenital FXIII deficiency (8).

While the 'classic' substrates for FXIII are the non-cross-linked fibrin polymers and, potentially, fibrinogen (9), other biologically important molecules have been shown to be substrates as well (10). Antifibrinolytic proteins such as α_2 -antiplasmin, thrombin-activatable fibrinolysis inhibitor (TAFI) and α_2 -macroglobulin are also incorporated into the clot, with cross-linking of α_2 -antiplasmin to fibrin being the principal mechanism whereby plasmin-mediated degradation of the fibrin clot is minimised (10). Furthermore, macromolecular components of plasma and the extracellular matrix, e.g. fibronectin and vitronectin are also cross-linked to fibrin, influencing the behaviour of fibroblasts, neutrophils and leukocytes through integrin signalling properties (10).

An increasing body of evidence indicates that FXIII is a multifunctional protein that, beyond a role in haemostasis, plays an important part in a wide range of other physiological and pathological

processes, including tissue repair and wound healing. The aim of this review article is to provide an overview of these diverse functions of FXIII and to highlight the potential for clinical use of FXIII replacement therapy in a range of conditions beyond congenital FXIII deficiency.

Perioperative bleeding

Adequate levels of FXIII are required in patients undergoing surgery to prevent or manage perioperative bleeding. In a study of 226 consecutive patients who underwent elective surgery, parameters relating to the final steps of coagulation were compared in those with unexplained intraoperative bleeding (defined according to prespecified clinical criteria) *versus* those with no such bleeding (11). Patients included in the study underwent different types of surgery in the departments of general surgery, neurosurgery, orthopaedics and urology. In total, 8.8% of the cohort developed “unexplained” (at the time) bleeding and, compared with “non-bleeders”, these patients had significantly lower levels of FXIII activity during and after surgery. These findings were paralleled by significantly lower availability of FXIII per unit thrombin generated and early loss of clot firmness of the whole blood clot, as assessed by the thromboelastometry (ROTEM) NATEM test, at all time points for “bleeders” *versus* “non-bleeders”. Of note, reduced clot firmness was detected at a time point when increased blood loss was not yet apparent, leading to the suggestion that early administration of FXIII may be beneficial in patients at risk of perioperative bleeding. In fact, this approach was subsequently evaluated prospectively in a randomised, placebo-controlled trial and found to be beneficial (see below) (12).

Inadequate levels of FXIII activity have been associated with an increased risk of postoperative haemorrhage. In a retrospective study of 1264 patients who underwent intracranial surgery, postoperative FXIII activity levels were measured in patients in whom coagulopathy was suspected despite normal results from standard coagulation monitoring (13). Of 34 such patients, 8 were found to have FXIII deficiency postoperatively, and all of these patients suffered a major postoperative haemorrhage. In contrast, only three of the 26 patients with suspected coagulopathy and normal FXIII activity levels experienced a postoperative haemorrhage, a difference that was statistically significant ($p < 0.00001$). A likely explanation for these phenomena is the fact that reduction of available FXIII activity is associated with reduced clot firmness as well as a decreased resistance of the clot to fibrinolysis (14, 15).

Clinical trial data

While these retrospectively collected clinical or *in vitro* data do not demonstrate causality between low FXIII activity levels and perioperative haemorrhage, this putative relationship is supported by data from randomised, placebo-controlled clinical trials of FXIII supplementation. In a proof-of-concept trial in elective gastrointestinal cancer surgery, loss of maximum clot firmness was significantly attenuated when FXIII concentrate (30 international unit [IU]/kg)^a was administered early during surgery ($p=0.004$ *versus* placebo, **Figure 1A**) in patients at risk (12). Significant reductions in the secondary endpoints of blood loss (**Figure 1B**) and fibrinogen consumption (**Figure 1C**) were also observed following FXIII concentrate administration (12). In a randomised, placebo-controlled study of FXIII concentrate (1250 or 2500 IU) in 75 patients undergoing coronary surgery, postoperative blood loss and blood product transfusion were significantly reduced in those with a post-administration FXIII level of $\geq 70\%$ *versus* a level $< 70\%$ (16). Although these trials have demonstrated positive outcomes of using FXIII concentrate to reduce postoperative blood loss, the study by Korte *et al.* was a small single centre study and did not evaluate blood loss as a primary endpoint (12), while the study by Godje *et al.* only evaluated FXIII concentrate in all patients undergoing coronary surgery, rather than in those with low FXIII levels (16). Therefore, further trials are needed to fully evaluate the potential of FXIII concentrate in these patients and others at risk of perioperative bleeding.

Case reports

A clinical utility of FXIII supplementation to manage bleeding in patients undergoing surgery has also been suggested by a number of case reports. For example, a patient with clopidogrel-related refractory bleeding following coronary artery bypass graft surgery was reported to have benefitted from the use of FXIII concentrate plus fibrinogen concentrate, after the administration of packed red blood cells, fresh frozen plasma, platelet concentrate, high-dose aprotinin, desmopressin, and recombinant activated factor VII had failed to stop the bleeding (17).

In another patient requiring major abdominal intervention for liver rupture, addition of FXIII concentrate for the correction of repeatedly occurring low preoperative FXIII activity (50%) pre-, intra- and perioperatively led to normalisation of FXIII activity and to the interruption of secondary bleeding because of low FXIII activity; this case provides evidence and insight into the fact that the half-life of FXIII is dramatically shortened during a state of high consumption. The subsequent postoperative course was uneventful in this patient (18).

In the same article, the authors describe a third patient who received a massive transfusion during emergency surgical treatment for multiple traumatic injuries. The resulting FXIII deficiency was

treated by administration of FXIII concentrate. Additional FXIII concentrate administration was used to address the ensuing generalised inflammation, sepsis and disseminated intravascular coagulation with bleeding, guided by timely measurements of FXIII activity (18).

All three cases demonstrate that measurement of FXIII activity in the perioperative setting is of utmost importance in the identification of patients that can benefit from FXIII concentrate therapy; this is especially important in light of the strong evidence that FXIII replacement therapy in patients undergoing cardiac surgery is not beneficial if their FXIII activity is normal to begin with (19).

In rare instances, FXIII deficiency is not related to a consumption process but occurs due to an inhibitor. In a recent case report by Hayashi *et al.* (20) a 75-year-old patient who presented with an enlarged subcutaneous haematoma following tooth extraction, despite no previous history of bleeding diathesis or familial bleeding, was described. FXIII activity was markedly decreased (<3%), while dot-blotting revealed the presence of immunoglobulin bound to FXIII-A subunit; evaluation of fibrin cross-linking revealed delayed formation of fibrin γ -chain dimers and α -chain polymers. The bleeding tendency in this patient was controlled by infusion of FXIII concentrate combined with immunosuppressive therapy (oral prednisolone) (20).

Management guidelines

The potential of FXIII for the management of perioperative bleeding is reflected in recent clinical practice guidelines. The guidelines established by the Society of Thoracic Surgeons Blood Conservation Task Force mention the use of blood derivatives, including FXIII, as an area of major revision (21). In addition, recent guidelines from the European Society of Anaesthesiology (ESA) on the management of severe perioperative bleeding note: *“in cases of ongoing or diffuse bleeding and low clot strength despite adequate fibrinogen concentrations, it is likely that FXIII activity is critically reduced. In cases of significant FXIII deficiency (i.e. <60% activity), we suggest that FXIII concentrate (30 IU/kg) can be administered”* (22).

Thus, there is evidence that acquired FXIII deficiency in the perioperative setting represents an interesting and probably under-recognised target to improve perioperative outcome. Clearly, immediate identification of such patients would be an important step forward. However, this needs close collaboration with the hospital laboratory, as FXIII assays with short turnaround times are not yet readily available in many hospital laboratories.

Angiogenesis and the role of thrombospondin

There are multiple lines of evidence to suggest that the impaired wound healing seen in patients with congenital FXIII deficiency stems, at least in part, from the proangiogenic properties of FXIII. More than a decade ago, it was reported that endothelial cells adhere to activated FXIII (FXIIIa) in an integrin-dependent manner (23, 24). In addition, both FXIII and FXIIIa were shown to mediate the interaction of platelets with endothelial cells by bridging between endothelial $\alpha_v\beta_3$ and platelet glycoprotein IIb/IIIa integrins (24). Using a range of *in vitro* assays, Dardik *et al.* (25) demonstrated that FXIIIa dose-dependently enhanced endothelial tube formation, increased endothelial cell migration and the rate of thymidine incorporation, and decreased the number of apoptotic cells. After treatment of endothelial cells with FXIIIa, there was downregulation of thrombospondin-1 (TSP-1), as reflected in almost complete disappearance of TSP-1 mRNA and a marked reduction in TSP-1 protein levels (25). The antiangiogenic properties of TSP-1 suggest the potential significance of this observation for FXIIIa-mediated promotion of angiogenesis.

In vivo models also provide evidence for the proangiogenic effects of FXIIIa. In a neonatal heterotopic mouse heart allograft model, injection of thrombin-activated FXIII into the grafted tissue produced significantly more new vessels and significantly higher contractile performance compared with saline-injected graft tissue (26). In FXIII-knockout mice, the formation of new vessels into a subcutaneously injected Matrigel™ plug (a mixture that resembles the complex extracellular environment found in many tissues) was significantly decreased compared with control mice. This effect could be almost completely reversed by the addition of FXIIIa to the gel (26). In rats, addition of FXIII concentrate to a tibial defect filled with a biodegradable hydroxyapatite implant has been shown to stimulate in-growth of microvessels into the biomaterial. In contrast, in defects filled with hydroxyapatite alone, formation of capillaries was limited to the host bone–hydroxyapatite surface (27).

The inhibitory effect of FXIIIa on TSP-1 expression observed in *in vitro* and *in vivo* studies provides an insight into the mechanism by which this coagulation factor promotes angiogenesis. TSP-1 is one of the best characterised antiangiogenic factors (28) and has been shown to induce endothelial cell apoptosis and inhibit neovascularisation in sponge implants in mice with severe combined immunodeficiency. This is mediated through increased expression of the proapoptotic protein Bax, decreased expression of the antiapoptotic protein Bcl-2, and activation of the caspase cell-death pathway through processing of caspase-3 into smaller proapoptotic forms (29).

The importance of TSP-1 in angiogenesis is demonstrated by additional animal studies. In transgenic mice, targeted overexpression of TSP-1 in the skin was associated with potent inhibition of cutaneous tissue repair, granulation tissue formation and wound angiogenesis (30). The observation that TSP-1 was not associated with major alterations in cutaneous vascular architecture or microvascular permeability suggests that chronic overexpression of TSP-1 in the skin preferentially affects wound-healing-associated angiogenesis rather than the angiogenesis associated with normal development and skin homeostasis. In a rabbit model of corneal neovascularisation, FXIIIa administration resulted in blood-vessel formation that was visible 48 hours after injection, whereas no such effect was observed following injection of saline into control eyes. Immunohistochemical analysis revealed that neovascularisation was accompanied by almost complete disappearance of TSP-1 in the cornea (25).

Molecular studies in human umbilical vein endothelial cells (HUVECs) have elucidated some of the processes whereby the proangiogenic effect of FXIIIa is mediated (31). Co-immunoprecipitation analysis demonstrated that FXIIIa cross-links $\alpha_v\beta_3$ integrin with vascular endothelial growth factor receptor 2 (VEGFR-2) and enhances non-covalent binding between these two receptors. Furthermore, FXIIIa was found to induce tyrosine phosphorylation of VEGFR-2 on both the cross-linked and non-covalent $\alpha_v\beta_3$ integrin–VEGFR-2 complexes. The effects of FXIIIa on complex formation and on tyrosine phosphorylation of VEGFR-2 were abolished by iodoacetamide treatment of FXIIIa. This treatment renders FXIII inactive, thus demonstrating that these effects were dependent on transglutaminase activity. Using quantitative real-time PCR analysis, FXIIIa was shown to cause upregulation of the transcription factors c-Jun and Egr-1. FXIIIa treatment of HUVECs resulted in binding of the transcription factor Wilm's tumour-1 (WT-1) but not Egr-1 to the TSP-1 promoter sequence, consistent with the hypothesis that WT-1 is involved in downregulation of TSP-1 expression.

The above evidence suggests an important role for FXIII in angiogenesis, and a model integrating these and related findings has been described (**Figure 2**) (32). Key elements of this model are the FXIII-mediated cross-linking of endothelial cell VEGFR-2 and $\alpha_v\beta_3$ integrin, and the downstream effects of this interaction, which lead to downregulation of TSP-1, ultimately promoting angiogenesis and neovascularisation. This proangiogenic activity may, in part, be responsible for the role of FXIII in tissue repair and remodelling, indicating that FXIII supplementation may have therapeutic potential in some types of wound healing.

Systemic sclerosis (scleroderma)

Systemic sclerosis (SSc), also known as scleroderma, is a severe autoimmune connective tissue disease that is characterised by early involvement of the microcirculation and immune system, fibroblast activation and increased extracellular matrix component production (33). The disease process results in diffuse arteriolo–capillary damage and tissue fibrosis. Potentially fatal involvement of major organs such as kidney and lung is common in advanced stages of the disease.

Owing to the proangiogenic effect of FXIII, there is potential for the use of FXIII treatment in patients with systemic sclerosis, who have a complex perturbation of connective tissue repair, fibrosis and altered vascular function. Many facets of the disease could potentially be modulated by FXIII. Indeed, small studies have shown some indications of benefit of FXIII treatment in this patient population.

Pathophysiological findings in systemic sclerosis

Upregulation of TSP-1 has been demonstrated in a number of studies of systemic sclerosis in the skin. This includes increased gene expression with upregulated mRNA (34, 35) and also increased protein expression detected by immunostaining and analysis of skin and explanted dermal fibroblast cultures (36). In recent studies, levels of TSP-1 mRNA have been correlated with the severity of skin fibrosis assessed by the modified Rodnan skin score (37). Strong upregulation of TSP-1 has been documented in affected and unaffected skin of patients with early diffuse systemic sclerosis (36). In addition, FXIIIa has been shown to inhibit collagen deposition *in vitro* (38), providing a further rationale for the potential use of FXIII in the setting of systemic sclerosis. Moreover, a genetically determined mouse model of systemic sclerosis, in which transforming growth factor- β (TGF- β) signalling is increased in fibroblasts, demonstrated high levels of TSP-1 expression, and this was the most upregulated transcript in skin fibroblasts of this mouse model in microarray analysis (39). This is important because TSP-1 is implicated as a key activator of latent TGF- β ligand and germ line deletion of TSP-1 replicates very closely the phenotype of TGF- β 1 knockout in mice (40). A study using the fibroblast populated collagen lattices model of matrix contraction showed that TSP-1 is a key mediator of enhanced contractility of lesional fibroblasts in systemic sclerosis, indicating that strategies that interfere with TSP-1 might be viable antifibrotic therapies (34).

Clinical trial data

Several preliminary studies have demonstrated a possible positive effect of FXIII concentrate treatment in patients with systemic sclerosis (**Table 1**) (41–48). These studies differ with respect to

patient profiles, FXIII concentrate regimens, duration of treatment, and outcome measures reported. However, promising trends were apparent with respect to skin sclerosis and improvement of arthralgia, pulmonary function, and Raynaud's phenomenon (41-48). Common limiting features of these studies were the relatively small sample sizes and, with the exception of the randomised, placebo-controlled trial by Guillemin and coworkers (43), the lack of a comparator group.

Despite these initial promising results, the potential benefits of FXIII treatment in systemic sclerosis have not been fully evaluated clinically, possibly owing to the strict regulation of the use of FXIII following the human immunodeficiency virus (HIV) epidemic (49). However, the availability of FXIII replacement therapies with improved safety profiles may now allow the potential benefits of FXIII treatment in this setting to be more fully investigated. Results from studies demonstrating the effect of FXIII on TSP-1 and angiogenesis (25, 26, 31) have generated a renewed interest in the potential therapeutic use of FXIII concentrate in systemic sclerosis. Nevertheless, as clinical data are so far only available from preliminary studies with small patient populations, appropriately designed and powered studies are needed to further investigate the use of FXIII concentrate in this regard.

Bacterial infections and wound healing

Bacterial infections

There is convincing evidence that FXIII plays an important role in host defence against invasive bacteria (50-52). In normal plasma, the induction of coagulation by *Streptococcus pyogenes* results in immobilisation of bacterial cells within the clot, with transmission electron microscopy revealing that the cells are cross-linked to fibrin fibres at multiple interaction sites (53). This bacterial entrapment within the plasma clot was shown to be FXIII-dependent; cross-linking was not observed when FXIII-deficient plasma was used. Immunostaining with a gold-labelled antibody against N- ϵ - γ -glutamyl-lysine elucidated further the nature of the interaction, revealing covalent interaction between one terminal of streptococcal M1 surface protein and a globular domain of fibrinogen (**Figure 3**) (53).

In a model of streptococcal skin infection, wild-type mice developed signs of tissue damage and severe pathological inflammation at the site of infection. When bacterial load was determined in blood, spleen and liver in these animals, colonisation was found to be significantly decreased by FXIII concentrate injection compared with non-treated controls (data for blood presented in **Figure 4**) (53). Although the effects of FXIII concentrate treatment on FXIII-deficient mice were not investigated in this study, results from patient biopsies provided further evidence of a role for FXIII in the immobilisation of streptococcal bacteria. FXIII-dependent bacterial killing and cross-linking of

streptococcal M1 protein to fibrin networks was detected in tissue biopsy material from patients with streptococcal necrotising fasciitis (53), suggesting that the mechanisms observed in mice also take place in clinical situations.

Additional studies have shown that FXIII also cross-links fibrin to surface proteins from other bacterial species such as *Escherichia coli* and *Staphylococcus aureus* (54). In the case of *S. aureus*, there is evidence that von Willebrand Factor binding protein (vWbp) secreted by colonising cells activates FXIII in a non-proteolytic manner and recruits fibronectin to staphylococcal clots (55). This has been interpreted as evidence of a mechanism whereby *S. aureus* modulates host immune responses to infection. The observation of analogous cross-linking of bacterial surface proteins from *S. aureus* and *E. coli* indicates that such cross-linking is an immune defence mechanism against multiple bacterial species and suggests that FXIII administration may have potential benefit in patients with invasive infections such as necrotising fasciitis.

Patients with sepsis have been shown to have lower FXIII-A and FXIII cross-linking activity levels than healthy individuals (56) and, in an experimental sepsis model in rats, FXIII was shown to protect mucosal capillary perfusion against endotoxin-induced impairment (57). However, other data have suggested that FXIII may also have negative effects in sepsis, i.e. increasing the risk of intravascular thrombosis (58).

The involvement of FXIII in innate immunity extends to proteins of the complement system. Functional proteomics data show that complement C3, the central component of the complement system, is a novel component of plasma clots and has an antifibrinolytic action (59). Other data show that complement C3 is a substrate for FXIIIa, and that incorporation of this protein into clots occurs by covalent cross-linking by FXIIIa (60, 61). In a further demonstration of the interaction between FXIII and the complement system, it has been shown that mannan-binding lectin-associated serine protease-1 (MASP-1) of the complement lectin pathway activates FXIII and is involved in fibrin clot formation (62).

FXIII also interacts with cells of the immune system (reviewed by Bagoly *et al.*) (63), being activated by human neutrophil elastase and downregulated by granulocyte proteases. Furthermore, FXIIIa enhances monocyte proliferation and migration, and inhibits monocyte apoptosis (64). Although some investigators have suggested that monocytes and macrophages are a source of plasma FXIIIa, arising from a non-classical secretory pathway (63, 65), this has not been shown unequivocally.

Within the context of infectious disease conditions, FXIII has been implicated in the entrapment of various bacteria, and has been shown to interact with components of the immune system. This

aspect of the physiological role of FXIII certainly warrants more examination, as does any potential benefit for FXIII supplementation for the treatment of bacterial infections.

Wound healing

Impaired wound healing was noted in the original description of a patient with congenital FXIII deficiency (7), and subsequent reports have documented that up to 29% of those with severe congenital FXIII deficiency exhibit poor wound healing (5, 66, 67). The multiple FXIII-dependent processes that are involved in wound healing are depicted in **Figure 5** (52).

A key role for FXIII in wound healing has been demonstrated in FXIII-deficient transgenic mice, where healing of an excisional wound was markedly delayed compared with healing in normal mice or in FXIII^{-/-} mice receiving FXIII supplementation (68). Impaired healing was accompanied by cellular and tissue defects, and these were also corrected by FXIII supplementation. A role for FXIII in wound healing has also been demonstrated in a rat burn model in which FXIII deficiency was induced by treatment with CCl₄ (which caused hepatic injury) (69), and in a bone-healing model in sheep (70). Another relevant mechanism for altered wound healing in FXIII deficiency is through interaction with TSP-1 and TGF- β activation as discussed above in relation to the pathogenesis of systemic sclerosis.

Clinical trial data in leg-ulcer patients

An early study in patients with leg ulcers noted decreased FXIII activity in patients with either post-phlebitic syndromes, post-phlebitic ulcers, varicose leg ulcer or mixed leg ulcers compared with those without venous disease (71). Subsequent clinical evaluations of topical treatment of venous leg ulcers with FXIII have shown promising results in small case studies and trials (72-75). In a randomised, double-blind, placebo-controlled trial in 30 patients with chronic venous leg ulcers, topical application of FXIII concentrate was shown to produce a significant reduction in ulcer size compared with placebo, and this was accompanied by a significant reduction in fibrinolytic activity in tissue samples (75). In another placebo-controlled trial of 24 patients, a significantly greater daily reduction in ulcer size was observed in FXIII concentrate-treated patients with small leg ulcers (<1000 mm²) relative to those with larger ulcers (>1000 mm²) ($p < 0.015$), although there was no significant difference between treated patients and controls (74). Interestingly, genotype/phenotype studies in humans have shown that the FXIII V34L polymorphism affects chronic venous leg ulcer size, healing time and response to superficial venous surgery, with healing time after superficial venous surgery increased in FXIII 34V homozygotes and ulcer size inversely related to the number of FXIII 34L alleles (76). This is biologically plausible because the FXIII 34L variant is associated with a faster rate of transglutaminase activation compared with the FXIII 34V variant (77, 78), an effect that

could be predicted to strengthen the extracellular matrix, and increase fibroblast migration/proliferation, and angiogenesis (earlier reports of increased transglutaminase activity (79) may have been observed due to incomplete thrombin activation but were later disproven (78)).

These studies indicate that FXIII may play an important role in the healing of leg ulcers. However, they do have some limiting features, such as the low patient numbers and, while two of the studies were placebo-controlled (74, 75), future larger, controlled clinical trials are required to determine the therapeutic potential of FXIII administration for wound healing of venous leg ulcers.

Wound healing after myocardial infarction

Experimental evidence from transgenic mice indicates that FXIII has a role in wound healing after myocardial infarction (MI) (80). Evaluation of myocardial repair in FXIII-deficient mice demonstrated that FXIII^{-/-} and FXIII^{+/-} mice died from left ventricular rupture within 5 days after experimental MI, whereas FXIII^{-/-} animals that received FXIII replacement therapy had a normal rate of survival. Molecular imaging detected significantly higher FXIII activity in wild-type mice and supplemented FXIII^{-/-} mice compared with untreated FXIII^{-/-} animals. Migration of neutrophils into the infarct region was significantly reduced in FXIII^{-/-} mice compared with wild-type animals, and this reduction could be partially corrected in FXIII^{-/-} animals by administration of FXIII. *In vivo* imaging showed that post-MI left ventricular dilatation was significantly attenuated in FXIII-treated mice compared with control animals post MI (81). An imbalance in extracellular matrix turnover (upregulation of metalloproteinase-9 expression/downregulation of collagen expression) was observed in FXIII^{-/-} mice after MI. This may potentially explain the cardiac rupture that was consistently observed in these transgenic animals (80).

These animal findings appear to have clinical relevance as case studies indicate that patients presenting with acute myocardial rupture following MI are found to have significantly reduced levels of FXIII relative to controls with uncomplicated MI (81, 82). In one patient with cardiac rupture who underwent valve replacement because of mitral valve insufficiency secondary to a papillary-muscle rupture, postoperative healing was delayed until FXIII supplementation was implemented (82). Together with the results from studies in mice (80), these case studies suggest that FXIII is implicated in tissue repair following MI (81, 82), and FXIII supplementation may have a positive effect on the rate of wound healing in this clinical setting; however, robust clinical data are lacking and larger prospective studies are required.

Future perspectives

In addition to its presence in plasma, FXIII-A can also be found in various cells including platelets, monocytes, macrophages, chondrocytes, osteoblasts and osteoclasts (as reviewed by Muszbeck 2011 (83)). There is evidence to support a role for cellular FXIII-A in several processes, including proliferation and migration of monocytes and fibroblasts (64), preadipocyte proliferation and energy metabolism (84), promotion of fibronectin matrices (85, 86) and osteoblast matrix secretion and deposition (87). This suggests that cellular FXIII-A is involved in a range of physiological and pathological functions in addition to those for plasma FXIII discussed within this review, and that further research into the potential role of FXIII in arthritis progression, cartilage repair, bone formation and adipogenesis may be warranted. As the mechanism of activation and functional roles of plasma and cellular FXIII may be different, the use of current FXIII replacement therapies to correct defective cellular FXIII-A function also remains to be evaluated.

Summary and conclusions

FXIII concentrate (human) has supplanted cryoprecipitate and fresh frozen plasma for the treatment of patients with congenital FXIII deficiency because the latter products carry a risk for transmissible disease, and plasma transfusion may induce transfusion-related acute lung injury (88). Indeed, FXIII concentrate (human) is recommended in management guidelines for treatment of congenital FXIII deficiency (8). Replacing FXIII in these patients restores the integrity of the last steps of the coagulation pathway, leading to restoration of adequate fibrin clot structure and strength as well as normal resistance of the clot and its substrate, fibrinogen, to the fibrinolytic system. While a recombinant FXIII-2A product (NovoThirteen[®]/Tretten[®], NovoNordisk A/S, Copenhagen, Denmark) is licensed in European Union countries, Canada, and most recently in the USA, for use in patients with congenital FXIII A-subunit deficiency, this product is not licensed for patients who have a deficiency in the FXIII B-subunit (89, 90).

FXIII deficiency may also be acquired, and can be associated with severe perioperative bleeding in major surgical interventions such as in tumour, heart or orthopaedic surgery, as well as large wound surfaces such as burns, or chronic concomitant inflammatory diseases. Despite promising data from initial randomised, placebo-controlled trials (12, 16), additional data from appropriately designed clinical trials are required to understand fully the benefits of FXIII administration for patients at risk of or suffering from perioperative bleeding. In case reports in which FXIII concentrate was used to

manage perioperative bleeding, the results of routine coagulation tests were normal (18, 20), emphasising the need to use FXIII-specific tests in patients with unexplained perioperative bleeding.

There is an increasing body of evidence to support the view that FXIII also plays a key role in a range of physiological functions. Beyond a role in haemostasis, these functions include: 1) angiogenesis, through signalling that involves downregulation of TSP-1; 2) bacterial immobilisation, through cross-linking of bacterial surface proteins to fibrin within a plasma clot; 3) wound healing, through cross-linking of integrin components of plasma and extracellular matrix, and enhancement of cell adhesion.

While administration of FXIII concentrate may provide clinical benefits in the disease contexts described in this review, there are certain conditions in which FXIII-A may have unwanted effects. For example, fibrin accumulation in synovial joints is thought to play a part in pathogenic pathways leading to rheumatoid arthritis (91, 92). In these cases, the current FXIII replacement therapies available (FXIII concentrate and recombinant FXIII-A) may be detrimental rather than beneficial to patients.

In conclusion, clinical studies have demonstrated that FXIII administration may provide clinical benefits in a range of underexplored indications, including perioperative bleeding, systemic sclerosis, invasive bacterial infections such as necrotising fasciitis, and wound healing. These studies have generally been underpowered to allow definitive conclusions to be made, but the promising results to date support the case for further clinical evaluation of FXIII administration in appropriately designed and powered studies in these clinical settings.

Footnote

^aTo maintain consistency, and as international units (IU) and units (U) are equivalent, all FXIII concentrate doses used in the studies described within this review are denoted in IU (or IU/kg), although some data were originally reported in the cited articles using U (or U/kg).

Acknowledgements

Medical writing assistance was provided by Fishawack Communications Ltd and funded by CSL Behring GmbH.

References

1. Hsieh L, Nugent D. Factor XIII deficiency. *Haemophilia* 2008; 14: 1190–1200.
2. Yee VC, Pedersen LC, Le Trong I, et al. Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. *Proc Natl Acad Sci U S A* 1994; 91: 7296–7300.
3. Nugent DJ. Prophylaxis in rare coagulation disorders – factor XIII deficiency. *Thromb Res* 2006; 118 Suppl 1: S23–28.
4. Levy JH, Greenberg C. Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. *Transfusion* 2013; 53: 1120–1131.
5. Ivaskevicius V, Seitz R, Kohler HP, et al. International registry on factor XIII deficiency: a basis formed mostly on European data. *Thromb Haemost* 2007; 97: 914–921.
6. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. *J Thromb Haemost* 2012; 10: 615–621.
7. Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. *Thromb Diath Haemorrh* 1960; 5: 179–186.
8. National Hemophilia Foundation: MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. Available at: <http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=693>. Accessed 24 September, 2013.
9. Mosesson MW, Siebenlist KR, Hernandez I, et al. Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation. *J Thromb Haemost* 2008; 6: 1565–1570.
10. Richardson VR, Cordell P, Standeven KF, et al. Substrates of Factor XIII-A: roles in thrombosis and wound healing. *Clin Sci (Lond)* 2013; 124: 123–137.
11. Wettstein P, Haeberli A, Stutz M, et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. *Anesth Analg* 2004; 99: 1564–1569.
12. Korte WC, Szadkowski C, Gahler A, et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. *Anesthesiology* 2009; 110: 239–245.
13. Gerlach R, Raabe A, Zimmermann M, et al. Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures. *Surg Neurol* 2000; 54: 260–264.

14. Jambor C, Reul V, Schnider TW, et al. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood. *Anesth Analg* 2009; 109: 1023–1028.
15. Theusinger OM, Baulig W, Asmis LM, et al. In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM). *Thromb Haemost* 2010; 104: 385–391.
16. Godje O, Gallmeier U, Schelian M, et al. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. *Thorac Cardiovasc Surg* 2006; 54: 26–33.
17. von Heymann C, Schoenfeld H, Sander M, et al. Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates? *Heart Surg Forum* 2005; 8: E39–41.
18. Lechner C. Clinical experience in perioperative bleeding and wound healing – a case collection. *Clinicum*.
19. Karkouti K, von Heymann C, Jespersen CM, et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. *J Thorac Cardiovasc Surg* 2013; 146: 927–939.
20. Hayashi T, Kadohira Y, Morishita E, et al. A case of acquired FXIII deficiency with severe bleeding symptoms. *Haemophilia* 2012; 18: 618–620.
21. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. *Ann Thorac Surg* 2011; 91: 944–982.
22. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. *Eur J Anaesthesiol* 2013; 30: 270–382.
23. Dallabrida SM, Falls LA, Farrell DH. Factor XIIIa supports microvascular endothelial cell adhesion and inhibits capillary tube formation in fibrin. *Blood* 2000; 95: 2586–2592.
24. Dardik R, Shenkman B, Tamarin I, et al. Factor XIII mediates adhesion of platelets to endothelial cells through alpha(v)beta(3) and glycoprotein IIb/IIIa integrins. *Thromb Res* 2002; 105: 317–323.
25. Dardik R, Solomon A, Loscalzo J, et al. Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression. *Arterioscler Thromb Vasc Biol* 2003; 23: 1472–1477.

26. Dardik R, Leor J, Skutelsky E, et al. Evaluation of the pro-angiogenic effect of factor XIII in heterotopic mouse heart allografts and FXIII-deficient mice. *Thromb Haemost* 2006; 95: 546–550.
27. Kilian O, Fuhrmann R, Alt V, et al. Plasma transglutaminase factor XIII induces microvessel ingrowth into biodegradable hydroxyapatite implants in rats. *Biomaterials* 2005; 26: 1819–1827.
28. Mirochnik Y, Kwiatek A, Volpert OV. Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. *Curr Drug Targets* 2008; 9: 851–862.
29. Nor JE, Mitra RS, Sutorik MM, et al. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. *J Vasc Res* 2000; 37: 209–218.
30. Streit M, Velasco P, Riccardi L, et al. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. *EMBO J* 2000; 19: 3272–3282.
31. Dardik R, Loscalzo J, Eskaraev R, et al. Molecular mechanisms underlying the proangiogenic effect of factor XIII. *Arterioscler Thromb Vasc Biol* 2005; 25: 526–532.
32. Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. *J Thromb Haemost* 2006; 4: 19–25.
33. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. *N Engl J Med* 2009; 360: 1989–2003.
34. Chen Y, Leask A, Abraham DJ, et al. Thrombospondin 1 is a key mediator of transforming growth factor beta-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism. *Fibrogenesis Tissue Repair* 2011; 4: 9.
35. Mimura Y, Ihn H, Jinnin M, et al. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. *Am J Pathol* 2005; 166: 1451–1463.
36. Avouac J, Clemessy M, Distler JH, et al. Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis. *Rheumatology (Oxford)* 2011; 50: 1494–1504.
37. Farina G, Lafyatis D, Lemaire R, et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. *Arthritis Rheum* 2010; 62: 580–588.
38. Paye M, Nusgens BV, Lapiere CM. Factor XIII of blood coagulation modulates collagen biosynthesis by fibroblasts in vitro. *Haemostasis* 1989; 19: 274–283.

39. Denton CP, Zheng B, Evans LA, et al. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. *J Biol Chem* 2003; 278: 25109–25119.
40. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. *Cell* 1998; 93: 1159–1170.
41. Delbarre F, Godeau P, Thivolet J. Factor XIII treatment for scleroderma. *Lancet* 1981; 2: 204.
42. Euller-Ziegler L, Corolleur YR, Marcou J, et al. [Long-term treatment of systemic scleroderma with coagulation factor XIII. Developmental monitoring, especially of respiratory function]. *Rev Rhum Mal Osteoartic* 1984; 51: 503–505.
43. Guillevin L, Chouvet B, Mery C, et al. Treatment of progressive systemic sclerosis using factor XIII. *Pharmatherapeutica* 1985; 4: 76–80.
44. Guillevin L, Chouvet B, Mery C, et al. [Treatment of generalized scleroderma with factor XIII. Study of 25 cases]. *Rev Med Interne* 1982; 3: 273–277.
45. Guillevin L, Euller-Ziegler L, Chouvet B, et al. [Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up]. *Presse Med* 1985; 14: 2327–2329.
46. Maekawa Y, Nogita T, Yamada M. Favorable effects of plasma factor XIII on lower esophageal sphincter pressure of progressive systemic sclerosis. *Arch Dermatol* 1987; 123: 1440–1441.
47. Marzano AV, Gasparini G, Colonna C, et al. Treatment of generalized scleroderma and generalized morphea with coagulation factor XIII. *Eur J Dermatol* 1995; 5: 459–466.
48. Thivolet J, Perrot H, Meunier F, et al. [Therapeutic action of coagulation factor XIII in scleroderma. 20 cases]. *Nouv Presse Med* 1975; 4: 2779–2782.
49. Jullien D, Souillet AL, Faure M, et al. Coagulation factor XIII in scleroderma. *Eur J Dermatol* 1998; 8: 231–234.
50. Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. *Int J Hematol* 2012; 95: 362–370.
51. Schroeder V, Kohler HP. New developments in the area of factor XIII. *J Thromb Haemost* 2013; 11: 234–244.
52. Soendergaard C, Kvist PH, Seidelin JB, et al. Tissue-regenerating functions of coagulation factor XIII. *J Thromb Haemost* 2013; 11: 806–816.
53. Loof TG, Morgelin M, Johansson L, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. *Blood* 2011; 118: 2589–2598.

54. Wang Z, Wilhelmsson C, Hyrsi P, et al. Pathogen entrapment by transglutaminase – a conserved early innate immune mechanism. *PLoS Pathog* 2010; 6: e1000763.
55. Thomer L, Schneewind O, Missiakas D. Multiple ligands of von Willebrand factor-binding protein (vWbp) promote *Staphylococcus aureus* clot formation in human plasma. *J Biol Chem* 2013; 288: 28283–28292.
56. Zeerleder S, Schroeder V, Lammle B, et al. Factor XIII in severe sepsis and septic shock. *Thromb Res* 2007; 119: 311–318.
57. Birnbaum J, Hein OV, Luhrs C, et al. Effects of coagulation factor XIII on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation in experimental endotoxemia. *Crit Care* 2006; 10: R29.
58. Lee SY, Chang SK, Lee IH, et al. Depletion of plasma factor XIII prevents disseminated intravascular coagulation-induced organ damage. *Thromb Haemost* 2001; 85: 464–469.
59. Howes JM, Richardson VR, Smith KA, et al. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. *Diab Vasc Dis Res* 2012; 9: 216–225.
60. Richardson VR, Schroeder V, Grant PJ, et al. Complement C3 is a substrate for activated factor XIII that is cross-linked to fibrin during clot formation. *Br J Haematol* 2013; 160: 116–119.
61. Nikolajsen CL, Scavenius C, Enghild JJ. Human complement C3 is a substrate for transglutaminases. A functional link between non-protease-based members of the coagulation and complement cascades. *Biochemistry* 2012; 51: 4735–4742.
62. Hess K, Ajjan R, Phoenix F, et al. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. *PLoS One* 2012; 7: e35690.
63. Bagoly Z, Katona E, Muszbek L. Factor XIII and inflammatory cells. *Thromb Res* 2012; 129 Suppl 2: S77–81.
64. Dardik R, Krapp T, Rosenthal E, et al. Effect of FXIII on monocyte and fibroblast function. *Cell Physiol Biochem* 2007; 19: 113–120.
65. Cordell PA, Kile BT, Standeven KF, et al. Association of coagulation factor XIII-A with Golgi proteins within monocyte-macrophages: implications for subcellular trafficking and secretion. *Blood* 2010; 115: 2674–2681.
66. Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. *Blood Rev* 1993; 7: 229–242.
67. Seitz R, Duckert F, Lopaciuk S, et al. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group. *Semin Thromb Hemost* 1996; 22: 415–418.

68. Inbal A, Lubetsky A, Krapp T, et al. Impaired wound healing in factor XIII deficient mice. *Thromb Haemost* 2005; 94: 432–437.
69. Ogawa T, Morioka Y, Inoue T, et al. Involvement of blood coagulation factor XIII in burn healing in the carbon tetrachloride-induced hepatic injury model in rats. *Inflamm Res* 1995; 44: 264–268.
70. Claes L, Burri C, Gerngross H, et al. Bone healing stimulated by plasma factor XIII. Osteotomy experiments in sheep. *Acta Orthop Scand* 1985; 56: 57–62.
71. Vanscheidt W, Hasler K, Wokalek H, et al. Factor XIII-deficiency in the blood of venous leg ulcer patients. *Acta Derm Venereol* 1991; 71: 55–57.
72. Hildenbrand T, Idzko M, Panther E, et al. Treatment of nonhealing leg ulcers with fibrin-stabilizing factor XIII: a case report. *Dermatol Surg* 2002; 28: 1098–1099.
73. Wozniak G, Dapper F, Alemany J. Factor XIII in ulcerative leg disease: background and preliminary clinical results. *Semin Thromb Hemost* 1996; 22: 445–450.
74. Peschen M, Thimm C, Weyl A, et al. Possible role of coagulation factor XIII in the pathogenesis of venous leg ulcers. *Vasa* 1998; 27: 89–93.
75. Herouy Y, Hellstern MO, Vanscheidt W, et al. Factor XIII-mediated inhibition of fibrinolysis and venous leg ulcers. *Lancet* 2000; 355: 1970–1971.
76. Gemmati D, Federici F, Catozzi L, et al. DNA-array of gene variants in venous leg ulcers: detection of prognostic indicators. *J Vasc Surg* 2009; 50: 1444–1451.
77. Ariens RA, Philippou H, Nagaswami C, et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. *Blood* 2000; 96: 988–995.
78. Balogh I, Szoke G, Karpatai L, et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. *Blood* 2000; 96: 2479–2486.
79. Anwar R, Gallivan L, Edmonds SD, et al. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. *Blood* 1999; 93: 897–905.
80. Nahrendorf M, Hu K, Frantz S, et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. *Circulation* 2006; 113: 1196–1202.
81. Nahrendorf M, Aikawa E, Figueiredo JL, et al. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. *Eur Heart J* 2008; 29: 445–454.

82. Nahrendorf M, Weissleder R, Ertl G. Does FXIII deficiency impair wound healing after myocardial infarction? PLoS One 2006; 1: e48.
83. Muszbek L, Bereczky Z, Bagoly Z, et al. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91: 931–972.
84. Myneni VD, Hitomi K, Kaartinen MT. Factor XIII-A transglutaminase acts as a switch between preadipocyte proliferation and differentiation. Blood 2014; 124: 1344–1353.
85. Cui C, Wang S, Myneni VD, et al. Transglutaminase activity arising from Factor XIIIa is required for stabilization and conversion of plasma fibronectin into matrix in osteoblast cultures. Bone 2014; 59: 127–138.
86. Barry EL, Mosher DF. Factor XIII cross-linking of fibronectin at cellular matrix assembly sites. J Biol Chem 1988; 263: 10464–10469.
87. Al-Jallad HF, Myneni VD, Piercy-Kotb SA, et al. Plasma membrane factor XIIIa transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics. PLoS ONE 2011; 6.
88. Meningitis Research Foundation: Race against time: meningitis and septicaemia can kill in hours, know the symptoms. Available at: <http://www.meningitis.org/assets/x/51490>. Accessed August 2, 2014.
89. Welch SB, Nadal S. Treatment of meningococcal infection. Arch Dis Child 2003; 88: 608–614.
90. Tunkel AR, Hartman BJ, Kaufman BA, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267–1284.
91. Busso N, Hamilton JA. Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2268–2279.
92. Hoppe B. Fibrinogen and factor XIII at the intersection of coagulation, fibrinolysis and inflammation. Thromb Haemost 2014; 112.

Legends to tables and figures

Table 1: Overview of studies of FXIII concentrate treatment in patients with systemic sclerosis. BID, “bis in die” (twice a day); IU, international unit; QD “*quaque die*” (once daily).

Figure 1. Effect of FXIII concentrate administration on clot parameters and blood loss in patients undergoing elective gastrointestinal surgery. A, change in maximum clot firmness of the whole blood clot assessed by the thromboelastometric NATEM test; B, median overall blood loss; C, change in fibrinogen content. Administration of FXIII concentrate 30 IU/kg or matching placebo (albumin) was started 15 minutes after the beginning of surgery. Bar chart created from data reported by Korte *et al.* (12).

Figure 2. Proposed mechanism of FXIII-induced angiogenesis (32). FXIII binds to endothelial-cell $\alpha_v\beta_3$ integrin, resulting in interaction between $\alpha_v\beta_3$ and vascular endothelial growth factor receptor-2 (VEGFR-2), and autophosphorylation (P) and activation of VEGFR-2. Activation of VEGFR-2 results in phosphorylation and activation of ERK, which promotes endothelial cell survival. Activated VEGFR-2 also results in increased endothelial cell proliferation, through phosphorylation of ERK and upregulation of Egr-1. Finally, activation of VEGFR-2 leads to upregulation of c-Jun, and downregulation of thrombospondin-1 (TSP-1) via the transcription factor Wilm’s tumour-1 (WT-1), resulting in increased cell proliferation, migration and survival.

Figure 3. Electron micrographic visualisation of FXIII-mediated cross-linking between streptococcal M1 protein and fibrinogen within a plasma clot (53). A, before FXIII-mediated cross-linking; B, after FXIII-mediated cross-linking; C, cross-linking detected by immunostaining fibrinogen–M1 protein complex with gold-labelled antibody against N- ϵ - γ -glutamyl-lysine. Panels D–F show schematic drawings of the fibrinogen (grey) and M1 protein (black) in panels A–C, respectively. Scale bars in panels C and F indicate 25 nm.

Figure 4. Effect of FXIII concentrate treatment on bacterial dissemination in wild-type mice infected with subcutaneous *Streptococcus pyogenes* (53). Treated mice received an injection of FXIII concentrate (human) 3 hours after infection. At 24 hours after infection, mice were killed and bacterial loads in the blood were determined. Data are the mean and individual values for 10 mice per group; * $p < 0.05$.

Figure 5. FXIII-dependent processes in wound healing (52). Plasma FXIII plays a role in wound healing through a number of mechanisms: A, Plasma FXIII enhances aggregation of platelets to the

endothelium at the site of injury; B, FXIIIa promotes the cross-linking of fibrin, thus increasing the integrity and tensile strength of the clot. FXIIIa also mediates incorporation of pathogens, structural macromolecules and fibrinolysis inhibitors into the fibrin clot; C, FXIIIa-induced cross-linking of the provisional matrix enables the infiltration of leukocytes, which interact with the matrix via integrins; D, Cross-linked macromolecules facilitate the invasion of fibroblasts and endothelial cells into the wound, enabling collagen deposition and angiogenesis. FXIII mediates the formation of a complex between $\alpha_v\beta_3$ integrin and VEGFR-2 on endothelial cells. This complex formation results in the activation of both receptors and the upregulation of downstream angiogenic signalling pathways (shown in **Figure 2**). FXIIIa, activated FXIII; IL-8, interleukin-8; PAI-2, plasminogen activator inhibitor-2; PDGF, platelet-derived growth factor; TAFI, thrombin-activatable fibrinolysis inhibitor; TGF- β , transforming growth factor- β ; VEGFR-2, vascular endothelial growth factor receptor 2; vWF, von Willebrand factor.

Table 1.


Study	N	Treatment regimen	Main findings
Thivolet <i>et al.</i> (1975)(48) and Delbarre <i>et al.</i> (1981)(41)	20	FXIII concentrate 250 IU BID for 2 weeks to 6 months	<ul style="list-style-type: none">• Definite beneficial effect in 7 patients and a more moderate effect in 5 patients• Improvement of arthralgia in 6 of 20 patients• Improvement in Raynaud's phenomenon in 9 of 16 patients• Normalisation of alveolar–capillary diffusion in 2 of 5 patients• No effect on oesophageal abnormalities in 4 patients who were evaluated radiologically, despite some improvement in dysphagia
Guillevin <i>et al.</i> (1982, 1985, 1985)(43-45)	25	FXIII concentrate 250 IU BID or placebo for 3 weeks (randomised, double-blind, crossover design)	<ul style="list-style-type: none">• Cutaneous improvement leading to improvement in functional index• Improvement of arthralgia in 10 of 25 patients
Euller-Ziegler <i>et al.</i> (1984)(42)	10	FXIII concentrate 1500 IU every 21 days for 6 to 37 months	<ul style="list-style-type: none">• Amelioration of cutaneous symptoms in 6 of 10 patients• Improvement of arthralgia in 9 of 10 patients• Vital capacity improved from an initial low value in 3 of 8 patients, but further diminished in 4 patients
Maekawa <i>et al.</i> (1987)(46)	2	FXIII concentrate 480 IU QD for 3 weeks	<ul style="list-style-type: none">• Improvement in lower oesophageal sphincter pressure in both patients; correlation with clinical improvement not reported

Marzano <i>et al.</i> (1995)(47)	12	FXIII concentrate 250 IU BID on alternate days for 10 doses, followed by 250 IU BID every 10 days for 6 months	<ul style="list-style-type: none"> • Marked improvement in skin sclerosis in 9 of 12 patients • Improvement of arthralgia in 7 of 11 patients • Improvement in passive joint mobility for at least one major joint in all 12 patients • Improvement in Raynaud's phenomenon in 3 of 8 patients • Improvement in vital capacity and diffusion capacity for carbon dioxide in 2 of 7 patients • No improvement in dysphagia
----------------------------------	----	--	---


Figures

Figure 1.

A



B



c




Figure 2.

Figure 2





Figure 3.



A scatter plot comparing bacterial load between two treatment groups. The y-axis is labeled "Log₁₀ CFU *S. pyogenes* per ml blood" and ranges from 2.0 to 3.5. The x-axis has two categories: "Non-treated" and "FXIII concentrate (human)-treated". Each category contains several black dots representing individual data points. A horizontal bar spans across both groups at approximately y=2.7, indicating statistical significance (*).

Treatment Group	Individual Data Points (Log ₁₀ CFU)
Non-treated	~2.3, ~2.3, ~2.6, ~2.6, ~2.9, ~3.4, ~3.4
FXIII concentrate (human)-treated	~2.3, ~2.3, ~2.3, ~2.3, ~2.3, ~2.3, ~2.3, ~2.3, ~2.6

Figure 5.

